Related Experiment Videos
Cloning immunoglobulin variable domains for expression by the polymerase chain reaction
R Orlandi1, D H Güssow, P T Jones
1Division of Experimental Oncology E, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
Summary
Researchers developed a new method using polymerase chain reaction (PCR) and specialized primers to clone and express antibody variable domains. This technique successfully created a chimeric antibody targeting human mammary carcinoma cells.
Area of Science:
- Immunology
- Molecular Biology
- Biotechnology
Background:
- Antibody variable domains are crucial for antigen binding.
- Efficient cloning and expression of these domains are essential for antibody engineering and therapeutic development.
- Current methods for cloning antibody variable domains can be complex and time-consuming.
Purpose of the Study:
- To develop a novel technique for amplifying and cloning mouse immunoglobulin heavy and light chain variable domains.
- To enable the force-cloning of these variable domains for subsequent sequencing and expression.
- To demonstrate the utility of this technique by cloning and expressing a chimeric antibody with potential therapeutic applications.
Main Methods:
- Design of oligonucleotide primers incorporating restriction sites for polymerase chain reaction (PCR) amplification of immunoglobulin variable domains.
- Application of the technique to five hybridoma antibodies for cloning and sequencing of their variable domains.
- Expression of a mouse-human chimeric antibody using the cloned variable domains.
Main Results:
- Successful amplification and cloning of mouse immunoglobulin heavy and light chain variable domains.
- Sequencing of variable domains from five hybridoma antibodies.
- Generation of a functional mouse-human chimeric antibody that binds to the human mammary carcinoma cell line MCF-7.
Conclusions:
- The developed primer-based PCR technique provides an efficient method for cloning and expressing antibody variable domains.
- This approach facilitates the generation of chimeric antibodies for potential therapeutic applications, such as targeting cancer cells.
- The technique holds promise for directly cloning antigen-binding specificities from immunoglobulin genes.